18/04/2026
Ubiquinol is marketed as the "active" form of CoQ10. The claim is that your body has to convert ubiquinone into ubiquinol before it can use it, so taking ubiquinol skips a step and gets absorbed more efficiently. This sounds logical. It is also not what the data shows.
The first thing to understand is that your body converts between these two forms constantly. CoQ10 is a redox molecule. It shuttles electrons in the mitochondrial respiratory chain by cycling between its oxidized state (ubiquinone) and its reduced state (ubiquinol). When you swallow ubiquinone, enterocytes in the small intestine reduce it to ubiquinol during absorption. When you swallow ubiquinol, some of it oxidizes back to ubiquinone before it even reaches the intestine because ubiquinol is inherently unstable in the presence of oxygen. Either way, 95-98% of CoQ10 circulating in your blood is in the ubiquinol form, regardless of which form was on the label. The body does not struggle with this conversion. It has been doing it efficiently for your entire life.
The bioavailability question is where the marketing diverges from the evidence. Lopez-Lluch et al. (2019, Nutrition) tested seven different CoQ10 formulations in a crossover study with 14 healthy adults. The AUC values ranged roughly 10-fold across the seven products. Mantle and Dybring (2020, Antioxidants) analyzed this data and identified the key finding: ubiquinol in a soft gel had approximately twice the AUC of ubiquinone that had not undergone crystal dispersion. That sounds like a win for ubiquinol. But ubiquinone that had been crystal-dispersed (a manufacturing process that breaks apart the CoQ10 crystal lattice so it dissolves in GI fluid) had roughly double the AUC of ubiquinol. The "premium" form sat in the middle. The formulation process mattered more than the redox state.
Crystal dispersion is the single largest variable. Without it, bioavailability drops by approximately 75% (Mantle 2020). After crystal dispersion, the carrier lipid composition and the physical format (soft gel with oil vs powder in a hard capsule) are the next most important factors. Taking CoQ10 with a fat-containing meal is also well-established to improve absorption because CoQ10 is highly lipophilic and requires bile salt micellization to cross the intestinal wall. These three variables, crystal dispersion, carrier format, and meal context, dwarf the ubiquinone vs ubiquinol distinction.
A 2020 randomized crossover study in 21 healthy elderly adults (Beg et al., Nutrients) compared ubiquinone capsules, ubiquinol capsules, and a water-soluble ubiquinone formulation head to head at 100mg single doses. The ubiquinol capsules showed 1.7-fold higher bioavailability than standard ubiquinone, but this difference was not statistically significant (p = 0.129). The water-soluble ubiquinone formulation was 2.4-fold higher than standard ubiquinone (p = 0.002). A reformulated ubiquinone outperformed ubiquinol.
Now the clinical outcomes, which is where this topic gets sharp. Fladerer and Grollitsch (2023, Current Cardiology Reports) conducted a systematic review of 28 clinical trials comparing ubiquinone and ubiquinol specifically for cardiovascular endpoints. Their findings were unambiguous. CoQ10 (ubiquinone) supplementation reduced cardiovascular death in heart failure patients. This has not been reported for ubiquinol. The effective doses in ubiquinone studies were lower than in ubiquinol studies. Positive long-term effects on cardiovascular mortality were observed only in ubiquinone trials. They explicitly recommend ubiquinone over ubiquinol for cardiovascular disease based on the available evidence.
The landmark trial is Q-SYMBIO (Mortensen et al., 2014, JACC Heart Failure). 420 patients with moderate to severe heart failure received 100mg ubiquinone three times daily or placebo for two years. The ubiquinone group showed a 43% reduction in cardiovascular death (HR 0.57, p = 0.026). The KiSel-10 trial (Alehagen et al., 2013) combined selenium with ubiquinone for four years and found a 53% reduction in cardiovascular mortality at five-year follow-up. No ubiquinol trial has produced cardiovascular mortality data remotely comparable to these results. That does not prove ubiquinol cannot produce similar outcomes. It means no one has demonstrated that it does.
One important context: Kaneka Corporation, based in Osaka, manufactures both Kaneka Q10 (ubiquinone) and Kaneka QH (ubiquinol). They developed the stabilization technology that made ubiquinol commercially viable as a supplement. Ubiquinol products carry a significant retail premium over ubiquinone, typically 2-3x the price per milligram. The foundational bioavailability study for Kaneka QH (Hosoe et al., 2007) was conducted by Kaneka employees in Kaneka laboratories. This does not invalidate the safety or bioavailability data. But it means the primary evidence base for ubiquinol's absorption advantage was generated by the company that profits from selling it at a higher margin than their own ubiquinone product. Independent head-to-head comparisons, like the Beg 2020 and Lopez-Lluch 2019 studies, have not confirmed a statistically significant ubiquinol advantage.
There are legitimate reasons someone might choose ubiquinol. Older adults with reduced oxidoreductase activity may theoretically benefit from receiving the reduced form. Patients with severe mitochondrial disorders or CoQ10 deficiency syndromes have shown clinical improvement with ubiquinol when ubiquinone failed, though this evidence is from case reports and small open-label studies, not RCTs. For the general population taking CoQ10 for cardiovascular health, energy, or statin-related myalgia, the evidence does not support paying a premium for ubiquinol over a well-formulated ubiquinone.
What actually matters: choose a soft gel with an oil carrier. Look for brands that use crystal dispersion or solubilized formulations. Take it with your fattiest meal of the day. These three decisions will affect your absorption more than whether the label says ubiquinone or ubiquinol. And if your goal is cardiovascular protection, every major trial that showed hard outcomes used ubiquinone.
Mantle & Dybring, Antioxidants, 2020
Fladerer & Grollitsch, Curr Cardiol Rep, 2023
Mortensen et al., JACC Heart Fail, 2014
Beg et al., Nutrients, 2020
